Vertex Pharmaceuticals vs Medtronic

Side-by-side comparison of AI visibility scores, market position, and capabilities

Medtronic leads in AI visibility (90 vs 71)
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Vertex Pharmaceuticals (VRTX) reported $10.7B revenue in FY2024, up 12% YoY. Global leader in cystic fibrosis treatment. Near-monopoly on CF drugs. HQ: Boston, MA. Market cap ~$110B.

AI VisibilityBeta
Overall Score
B71
Category Rank
#140 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
76
Gemini
72

About

Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.

Full profile
Medtronic logo

Medtronic

LeaderHealthcare Tech

Enterprise

World's largest medical device company with $32.4B FY2024 revenue; Hugo robotic surgery challenges Intuitive Surgical; MiniMed automated insulin system; Patient Monitoring spin-off 2024; NYSE: MDT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#126 of 290
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
85
Perplexity
97
Gemini
99

About

Medtronic plc is the world's largest medical device company, founded in 1949 by Earl Bakken and Palmer Hermundslie in a Minneapolis, Minnesota garage—where Bakken invented the first wearable external pacemaker—and now incorporated in Ireland with operational headquarters in Dublin, trading on NYSE (MDT). The company generated approximately $32.4 billion in revenues for fiscal year 2024 (ending April 26, 2024) under CEO Geoff Martha, spanning cardiovascular, neuroscience, surgical, and diabetes therapy technologies. Medtronic's 2015 acquisition of Covidien for $49.9 billion—at the time the largest medical device merger in history—added surgical instruments, patient monitoring, and respiratory interventions while enabling Irish incorporation that reduced the company's effective tax rate. In 2024, Medtronic announced the spin-off of its Patient Monitoring & Respiratory Interventions segment as an independent company (NewCo), sharpening focus on higher-margin, high-growth therapy areas.

Full profile

AI Visibility Head-to-Head

71
Overall Score
90
#140
Category Rank
#126
58
AI Consensus
53
stable
Trend
up
79
ChatGPT
85
76
Perplexity
97
72
Gemini
99
65
Claude
97
63
Grok
82

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.